Get Started. It's Free
or sign up with your email address
TOPIC FOR FINALS by Mind Map: TOPIC FOR FINALS

1. MEDCHEM

1.1. Intro

1.2. Antiviral

1.2.1. P1

1.2.2. P2

1.3. Antimalaria

1.4. Antileprotic & Antituberculosis

1.5. Antifungal & Antiprotozoal

1.6. Cholinergic

1.7. Anticholinergic

1.8. Adrenergic nervous system

1.8.1. P1

1.8.2. P2

1.9. Opiod analgesics

1.9.1. P1

1.9.2. P2

1.10. Anticancer

1.10.1. P1

1.10.2. P2

1.11. Antiulcer

1.11.1. P1

1.11.2. P2

1.12. Steroidal drugs

2. PA

2.1. Chemicals

2.2. Weighing

2.3. Errors

2.4. Intro HPLC

2.5. Selection & Optimization HPLC

2.6. UV Spectro

2.7. Analysis with UV Spectrophotometer

2.8. Complexometric Titration

2.9. Precipitation titration

2.10. Acid base titration

2.11. Oxidation-reduction titration

2.12. Mass spectroscopy

2.13. Fluorimetry

2.14. IR Spectroscopy

2.15. NMR Spectroscopy

3. PP2

3.1. Intro

3.2. Surfactants

3.2.1. P1

3.2.2. P2

3.2.3. P3

3.3. Suspension

3.3.1. P1

3.3.2. P2

3.3.3. P3

3.4. Rheology

4. PP3

4.1. Inpatient

4.1.1. P1

4.1.2. P2

4.2. Drug information serivice (DIS)

4.3. Galenical department

4.4. Outpatient

4.4.1. P1

4.4.2. P2

4.4.3. P3

4.5. Store

4.6. Councelling

4.7. Clinical service

4.7.1. P1

4.7.2. P2

4.8. Therapeutic drug monitoring (TDM)

4.9. Cytotoxic drug

5. CVC

5.1. Intro

5.2. Artherosclerosis

5.3. Hypertension

5.4. Hyperlipidimia

5.5. Angina pectoris

5.6. Shock

5.7. Stroke

5.8. Veous thromboembolism

5.9. Heart failure

5.10. Arterial fibrilation

5.11. Coagulants & Anti-coagulants drug

5.12. Fibrinolytic & Anti-platelet drug

6. CNS

6.1. Intro

6.2. Parkinson

6.3. Alzheimer

6.4. Epilepsy

6.5. Schizophrenia

6.6. Hypnotics

6.7. Opiod analgesic & antagonist & CNS stimulant

6.8. Antidepressant

6.9. Migraine

6.10. Anesthatics

7. DDF

7.1. Intro

7.2. Preformulation studies

7.3. Basic pharmaceutical process

7.4. Tablet

7.4.1. P1

7.4.2. P2

7.5. Powder & granules

7.6. Capsule

7.7. Formulation consideration

7.8. Plasma serum & urine data analysis

7.9. Bioavailability

7.10. Pharmacokinetic model

7.11. Non-linear kinetic

7.12. Multiple dosage regime

7.13. Sustained/controlled release